Investor Relations

AVEO Oncology is a biopharmaceutical company committed to developing targeted therapies through biomarker-driven insights to provide substantial improvements in patient outcomes where significant unmet medical needs exist. AVEO’s proprietary Human Response Platform™ has delivered unique insights into cancer and related disease biology that are being leveraged in the clinical development of its therapeutic candidates.

NASDAQ | AVEO (Common Stock)
$2.28 + 0.25
Stock chart for: AVEO.O.  Currently trading at $2.28 with a 52 week high of $3.50 and a 52 week low of $0.61.
06/01/15 4:00 p.m. ET
Data Provided by Thomson Reuters

Press Releases

AVEO Oncology to Present at Jefferies 2015 Global Healthcare ConferenceRead More
AVEO Oncology Announces New Corporate Headquarters in Cambridge, MassachusettsRead More
AVEO Oncology Announces Presentation of Final Results of Extension Study 902 and FDA Regulatory Feedback for Advancing Tivozanib in Renal Cell CarcinomaRead More